The company has market cap of $670.37 million. The Trust is formed by Energy Corporation of America (ECA) to own royalty interests in natural gas properties owned and operated by ECA in the Marcellus Shale formation in Greene County, Pennsylvania. The Trust does not conduct any activities or activities.
Armistice Capital Llc increased Synergy Pharmaceuticals Del (SGYP) stake by 37.1% reported in 2016Q4 SEC filing. Of those insider trades, 0 shares of Synergy Pharmaceuticals Inc. were purchased and 26,287 shares were sold. The company posted earnings of $2.31 M for the period end, compared to analysts’ anticipations of $1.98 M. For the same quarter last year, firm reported ($0.23) EPS. on consensus, experts expect that Synergy Pharmaceuticals to post ($1.09) earnings per share for the financial year.
Synergy Pharmaceuticals Inc.is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has “Buy” rating given on Thursday, August 10 by H.C. Wainwright. Phillips 66 (NYSE:PSX) has risen 0.77% since August 28, 2016 and is uptrending. (NASDAQ:SGYP)’s 14-day Relative Strength Index (RSI) has reached 28.33, putting it inside a neutral zone.
Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its quarterly earnings data on Wednesday, August 9th. It has underperformed by 15.93% the S&P500.The move comes after 9 months positive chart setup for the $42.95 billion company. During the same quarter in the previous year, the firm earned ($0.23) earnings per share. Ghost Tree Ltd accumulated 55,000 shares or 0.08% of the stock. Opus Capital Group Llc, a Ohio-based fund reported 167,984 shares.
Synergy Pharmaceuticals, Inc. (SGYP) has an Analysts’ Mean Recommendation of 2.
Investors sentiment decreased to 1.19 in 2016 Q4. Its up 0.39, from 1.02 in 2016Q3. Janney Montgomery Scott LLC now owns 30,200 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 6,500 shares in the last quarter. 27 funds opened positions while 47 raised stakes. The stock grabbed 26 new institutional investments totaling 6,640,639 shares while 39 institutional investors sold out their entire positions totaling 4,617,796 shares.
Synergy Pharmaceuticals, Inc.’s insider ownership stands at 0.2 percent, while its insider transaction is -3.04 percent. Modera Wealth Mgmt Limited Com invested in 0.02% or 10,500 shares. (NASDAQ:SGYP)’s stock was -51.07%. Cetera Advisor Net Ltd Llc holds 981 shares or 0.01% of its portfolio. Victory Cap Management reported 0% stake. Benjamin F Edwards And Inc accumulated 1,694 shares. 240,918 are owned by Credit Suisse Ag. They now have a United States dollars 10.5 price target on the stock. Rhumbline Advisers holds 0% or 200,076 shares in its portfolio. Vertical Research downgraded the stock to “Hold” rating in Thursday, April 21 report. Raymond James And has 61,615 shares for 0% of their portfolio. HC Wainwright set a $15.00 price target on shares of Synergy Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 10th. Therefore 88% are positive. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. Another trade for 6,500 shares valued at $23,335 was made by BRANCACCIO JOHN P on Friday, May 26.
Among 2 analysts covering Cantel Medical (NYSE:CMN), 1 have Buy rating, 0 Sell and 1 Hold. Synergy Pharmaceuticals Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Paulson & Co. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $18.00 price objective on shares of Synergy Pharmaceuticals in a report on Tuesday, May 23rd. Four equities research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company. Principal Gru reported 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Citigroup maintained Mosaic Co (NYSE:MOS) rating on Thursday, August 4. The company was initiated on Thursday, June 1 by Cantor Fitzgerald.
01/23/2017 – Synergy Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Roth Capital.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our daily email newsletter.